Simbikort

Simbikort – the pharmacological drug used for treatment of obstructive diseases of lungs.

Trade name Simbikort Turbukhaler

Structure and form of release

According to the instruction Simbikort is issued in the form of powder for the dosed inhalations. Active ingredients – будесонид, a formoterola a fumaratedihydrate. Also as excipient monohydrate of lactose is a part of drug.

Drug in the inhalers with the rotating dosers expected 60 or 120 doses is produced. The mouthpiece of an inhaler can rotate.

Contents of an inhaler are granules of white color and rounded shape.

Can contain in 1 dose of Simbikort: budesonida of 80 or 160 mkg, formoterola of a fumaratedihydrate of 4,5 mkg.

Pharmacological action of Simbikort

According to the instruction Simbikort is a combination of glucocorticosteroids and the selection a beta 2 adrenomimetik. Active ingredients show different mechanisms of influence and give the chance to use drug, both for stopping of attacks, and for a maintenance therapy of bronchial asthma.

Budesonid is an inhalation glucocorticoid and possesses antiinflammatory action. It reduces expressiveness of symptoms and reduces the frequency of exacerbations of bronchial asthma. At the same time at it is much lower than side effects, than at use of system glucocorticoids. As a result of action of a budesonid hypostasis of walls of bronchial tubes, products of slime and hyperreactivity of respiratory tracts decreases.

Formoterol is the selection antagonist of b2 of adrenergic receptors and causes relaxation of smooth muscles of respiratory tracts. Broncholitic action comes in 1-3 minutes after inhalation and lasts till 12 o'clock. The combination of a formoterol and a budesonid allows to reduce expressiveness of symptoms of bronchial asthma, to improve a functional condition of bronchial tubes and reduces the frequency of a recurrence of a disease.

According to responses Simbikort is well had by patients, including children's age (of 6 years).

At patients with a chronic obstructive pulmonary disease at heavy respiratory insufficiency against the background of Simbikort's use considerable improvement of a state was noted.

Indications to use

According to the instruction Simbikort is shown for treatment of the following states:

• bronchial asthma;
• chronic obstructive pulmonary disease (for patients with a severe form).

Contraindications to Simbikort's use

According to the instruction Simbikort is contraindicated at hypersensitivity to the making components, and also children up to 6 years.

With care Simbikort it is necessary to use at a pulmonary tuberculosis, fungal, virus or bacterial respiratory infections, a thyrotoxicosis, a diabetes mellitus, a pheochromocytoma, heavy arterial hypertension, aneurisms of any localization, heart failure of heavy degree, tachyarrhythmias.

Use during pregnancy and a lactation

Adequate clinical trials on Simbikort's use were not conducted during pregnancy. It is only necessary to appoint this drug when the potential advantage considerably exceeds risk for a fruit.

Now it is not known whether Simbikort's components get into breast milk. Therefore it is not recommended to use this drug during feeding by a breast.

Route of administration and Simbikort's doses

According to the instruction Simbikort is not recommended for treatment of bronchial asthma of an easy current. Selection of a dose of drug is carried out individually depending on disease severity.

To children 6 years are more senior Simbikort Turbukhaler is recommended in a dose of 80/4,5 mkg on 1-2 inhalations 2 times a day.

To children at the age of 12-17 years of a dose of Simbikort are similar to adults (1-2 inhalations in a dose of 80/4,5 mkg or 160/4,5 mg 2 times a day).

Simbikort Turbukhaler is recommended to adults in a dose of 80/4,5 mkg or 160/4,5 mkg on 1-2 inhalations 2 times a day. Increase in a dose to 4 inhalations in days is in case of need possible. At achievement of optimum control of symptoms of bronchial asthma against the background of Simbikort's reception, reduction of a dose to the smallest effective is possible. According to reviews Simbikort effectively helps for prevention of attacks of bronchial asthma and is simple in use.

The patients using this drug should consult regularly at the doctor for control of an optimum dose.

To patients with a chronic obstructive pulmonary disease about 2 inhalations Simbikort Turbukhaler of 160/4,5 mkg two times a day are usually appointed.

Side effect

According to reviews Simbikort seldom causes side effects. The most frequent side reactions are: tremor, headache and tachycardia. These symptoms are usually expressed moderately and independently pass within several days after the beginning of therapy. Also, according to reviews, Simbikort in rare instances can cause candidiases of a mucous membrane of an oral cavity and throat, a hoarseness, cough. Very seldom Simbikort, according to reviews, causes psychomotor excitement, concern, sleep disorders, bruises, allergic reactions, disturbances of a cordial rhythm.

Use of this drug can lead to increase in concentration of insulin in blood that needs to be considered at patients with a diabetes mellitus.

Overdose by Simbikort

Symptoms of overdose of a formoterol are: tremor, heartbeat, headache, nausea, vomiting, arrhythmia. At overdose of a budesonid of clinically significant reactions it was not noted. Symptomatic treatment.

At chronic reception of the raised Simbikort's doses emergence of systemic action of glucocorticosteroids (suppression of function of adrenal glands, a hypercorticoidism) is possible.

Interaction with other medicines

It is necessary to avoid Simbikort's combination and a ketokonazol.

Simbikort and a beta – adrenoblockers is not recommended to appoint at the same time (even in the form of eye drops).

Simultaneous use with quinidine, procaineamide, fenotiaziny, antihistaminic drugs, MAO inhibitors, tricyclic antidepressants can lead to emergence of ventricular arrhythmias.

Simbikort's interaction with other drugs used at treatment of bronchial asthma is noted.

Special instructions on Simbikort's use

According to the instruction Simbikort it is necessary to cancel gradually, it is not recommended to stop treatment sharply.

This drug is not intended for initial treatment of bronchial asthma.

Patients need to know that Simbikort's use has to be regular, even in the absence of disease symptoms. It is not necessary to begin treatment with this drug in the period of an exacerbation of bronchial asthma.

According to reviews Simbikort in rare instances can cause a paradoxical bronchospasm after inhalation. At emergence of this complication it is necessary to cancel this drug and to pick up alternative treatment.

At patients with a diabetes mellitus during Simbikort's use it is necessary to control the content of glucose in blood.